Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- HypoResusIndependent statistical analysis of Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR): Complete Statistical AnalysisIndependent statistical analysis of Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Hypothyroidism Treated With Calcitonin: Complete Statistical AnalysisIndependent statistical analysis of Hypothyroidism Treated With Calcitonin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03342001).
- Hypoxic Pulmonary Vasoconstriction Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of Hypoxic Pulmonary Vasoconstriction Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03733470).
- HYROSIndependent statistical analysis of HYbrid RObotic Surgery in Urology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05864040).
- Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata: Complete Statistical AnalysisIndependent statistical analysis of Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00731341).
- Hysteroscopic Lymphatic Mapping for Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Hysteroscopic Lymphatic Mapping for Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00671606).
- I-CAREIndependent statistical analysis of Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03119259).
- I-D-HEALTHIndependent statistical analysis of Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- I-gelIndependent statistical analysis of Comparison of I-gel to the Laryngeal Mask Airway: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00706823).
- I-KANIndependent statistical analysis of The I-KAN Study: Internet Insulin Education for Kansans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01408628).
- i-Matter: Investigating an mHealth Texting Tool for Embedding Patient-reported Data Into Diabetes Management: Complete Statistical AnalysisIndependent statistical analysis of i-Matter: Investigating an mHealth Texting Tool for Embedding Patient-reported Data Into Diabetes Management: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- I-SCREENIndependent statistical analysis of Increasing Screening for Cancer Using EHR-Nudges: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06177795).
- I-STAND R21: Reducing Sedentary Time in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of I-STAND R21: Reducing Sedentary Time in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02692560).
- I2PETHVIndependent statistical analysis of I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02323217).
- iAIM EDUIndependent statistical analysis of Harnessing Mobile Technology to Reduce Mental Health Disorders in College Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IASISIndependent statistical analysis of Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IATCIIndependent statistical analysis of IV Iron for the Anemia of Traumatic Critical Illness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01180894).
- iATTENDIndependent statistical analysis of The Improving ATTENDance to Cardiac Rehabilitation Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03646760).
- IBCSG 23-01Independent statistical analysis of IBCSG 23-01, a randomized trial of axillary lymph node dissection versus no axillary lymph node dissection in women with node-negative breast cancer and sentinel lymph node micrometastases.
- IBPSIndependent statistical analysis of Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03303391).
- Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis: Complete Statistical AnalysisIndependent statistical analysis of Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05399641).
- Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas: Complete Statistical AnalysisIndependent statistical analysis of Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00493454).
- Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02956382).
- Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03207555).
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01849263).
- Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IBSCIIndependent statistical analysis of The Relationship Between Irisin and Bone Health in Individuals With Spinal Cord Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IBU-ALS-1201Independent statistical analysis of Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02238626).
- Ibuprofen Extended-Release Dental Pain Study: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen Extended-Release Dental Pain Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00707057).
- Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03068897).
- Ibuprofen Sodium Tension Headache Study: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen Sodium Tension Headache Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01362491).
- Ibuprofen With or Without Acetaminophen for Low Back Pain: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen With or Without Acetaminophen for Low Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03554018).
- Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01229449).
- IC/BPSIndependent statistical analysis of Real-world Evidence Study on Cystistat: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05544695).
- iCareIndependent statistical analysis of iCare Stress Management e-Training for Dementia Family Caregivers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01378195).
- iCAREIndependent statistical analysis of Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04938661).
- iCAREIndependent statistical analysis of Intensive Combination Approach to Rollback the Epidemic in Nigerian Adolescents: UH3 Phase: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ICBTIndependent statistical analysis of Internet-based Cognitive Behavioural Therapy for Spanish Tinnitus Sufferers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04335929).
- ICEIndependent statistical analysis of Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00220740).
- Ice Immersion Using Virtual Reality & Augmented Reality: Complete Statistical AnalysisIndependent statistical analysis of Ice Immersion Using Virtual Reality & Augmented Reality: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04196686).
- ICECANIndependent statistical analysis of Interstitial Cystitis: Examination of the Central Autonomic Network: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03008382).